Gilead Sciences (GILD) Long-Term Investments (2009 - 2026)
Gilead Sciences' (GILD) quarterly Long-Term Investments came in at $983.0 million in Q1 2026, down 66.95% on a QoQ basis from $3.0 billion in Q4 2025.
Gilead Sciences (GILD) Long-Term Investments (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 17 years of Long-Term Investments data on file, last reported at $983.0 million in Q1 2026.
- Quarterly Long-Term Investments changed N/A year-over-year to $983.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $983.0 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 billion, changed N/A from the prior year.
- Long-Term Investments eased to $983.0 million in Q1 2026, from $3.0 billion in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $3.0 billion in Q4 2025 to a low of $983.0 million in Q1 2026.
- A 4-year average of $1.5 billion and a median of $1.3 billion in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments jumped 146.46% — and 2023, when it declined 9.83%.
- Tracing GILD's Long-Term Investments over 4 years: stood at $1.2 billion in 2022, then slipped by 6.59% to $1.2 billion in 2023, then jumped by 155.72% to $3.0 billion in 2025, then sank by 66.95% to $983.0 million in 2026.
- The last three Long-Term Investments figures came in at $983.0 million (Q1 2026), $3.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 3.73 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 983.00 Mn |
| Dec 31, 2025 | 2.97 Bn |
| Sep 30, 2025 | 2.01 Bn |
| Jun 30, 2025 | 1.91 Bn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.16 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.33 Bn |
| Dec 31, 2022 | 1.25 Bn |
| Sep 30, 2022 | 1.28 Bn |
| Jun 30, 2022 | 1.34 Bn |
| Mar 31, 2022 | 1.43 Bn |
| Dec 31, 2021 | 1.31 Bn |
| Sep 30, 2021 | 1.10 Bn |
| Jun 30, 2021 | 836.00 Mn |
| Mar 31, 2021 | 579.00 Mn |
| Dec 31, 2020 | 502.00 Mn |
| Sep 30, 2020 | 2.07 Bn |
| Jun 30, 2020 | 2.28 Bn |
| Mar 31, 2020 | 3.53 Bn |